Literature DB >> 4790607

In vitro evaluation of a new aminoglycoside derivative of kanamycin, a comparison with tobramycin and gentamycin.

K Ries, M E Levison, D Kaye.   

Abstract

Against more than 90% of 200 bacterial strains tested in vitro, the inhibitory concentration of gentamicin and tobramycin was 3.1 mug/ml and that of BB-K 8, a new semisynthetic aminoglycoside derivative of kanamycin, was 6.3 mug/ml.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4790607      PMCID： PMC444449          DOI： 10.1128/AAC.3.4.532

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  BB-K 8, a new semisynthetic aminoglycoside antibiotic.

Authors:  H Kawaguchi; T Naito; S Nakagawa; K I Fujisawa
Journal:  J Antibiot (Tokyo)       Date:  1972-12       Impact factor: 2.649

2.  Microbiological evaluation of BB-K 8, a new semisynthetic aminoglycoside.

Authors:  K E Price; D R Chisholm; M Misiek; F Leitner; Y H Tsai
Journal:  J Antibiot (Tokyo)       Date:  1972-12       Impact factor: 2.649

3.  In vitro evaluation of tobramycin, a new aminoglycoside antibiotic.

Authors:  M E Levison; R Knight; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1972-05       Impact factor: 5.191
  3 in total
  10 in total

1.  Penetration of amikacin into the aphakic eye.

Authors:  R T Kasbeer; G A Peyman; D R May; P I Homer
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1975-08-04

2.  In vitro activity, synergism, and testing parameters of amikacin, with comparisons to other aminoglycoside antibiotics.

Authors:  M T Kelly; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

3.  In vitro comparison of four aminoglycoside antibiotics: sisomicin, gentamicin, tobramycin, and BB-K8.

Authors:  M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

4.  Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli.

Authors:  J E Rosenblatt; P R Stewart
Journal:  Antimicrob Agents Chemother       Date:  1974-07       Impact factor: 5.191

5.  In vitro comparison of gentamicin, tobramycin, sisomicin, and netilmicin.

Authors:  K N Brown; J Benedictson; S Swanby
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

Review 6.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

7.  Amikacin (BB-K8) treatment of multiple-drug resistant Proteus infections.

Authors:  P M Sharp; C A Saenz; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

Review 8.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

9.  Single-dose daily gentamicin therapy in urinary tract infection.

Authors:  E Labovitz; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

10.  Tobramycin: maternal-fetal pharmacology.

Authors:  B Bernard; S J Garcia-Cazares; C A Ballard; L D Thrupp; A W Mathies; P F Wehrle
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.